10
Views
7
CrossRef citations to date
0
Altmetric
Nephrology: Original clinical scientific reports

Development of Anti-OKT3 Antibodies After OKT3 Treatment

, , , &
Pages 227-230 | Received 25 Nov 1994, Accepted 26 May 1995, Published online: 15 Feb 2010

REFERENCES

  • Birkeland SA, Svendsen V, Rohr N, Hansen BL, Elbirk A, Foged N, Køhler F. Use of monoclonal antibodies to T cells (OKT3) for treatment of acute cellular rejection after renal transplantation. Transplant Proc 1988; 20: 451–454.
  • Birkeland SA, Bach JF, Chatenoud L, Jørgensen KA, Strate M, Elbirk A, Rohr N, Svendsen V. First and second course of OKT3 monoclonal anti-T cell antibody for treatment of renal allograft rejection followed by testing for anti OKT3 IgM and/or IgG immunization. Transplant Proc 1990; 22: 221–222.
  • Chatenoud L, Baudrihaye MF, Chkoff N, Kreis H, Goldstein G, Bach JF. Restriction of the human in vivo immune response against the mouse monoclonal antibody OKT3. J. Immunol. 1986; 137: 830–838.
  • Chatenoud L. Humoral Immune Response Against OKT3. Transplant Proc 1993; 25, (Suppl 1): 68–73.
  • Cosimi AB. The clinical usefulness of antilymphocyte antibodies. Transplantation Proceedings 1983; 25: 583–589.
  • Cosimi AB, Burton RC, Colvin RB, et al. Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation 1981; 32: 535–539.
  • Delaney VB, Campbell WG, Nasr SA, McCue PA, Warshaw B, Whelchel JD. Efficacy of OKT3 monoclonal antibody therapy in steroid-resistant, predominantly vascular acute rejection. Transplantation 1988; 45: 743–748.
  • First MR, Schroeder TJ, Hurtubise PE, et al. Successful retreatment of allograft rejection with OKT3. Transplantation 1989; 47: 88–91.
  • Hansen BL, Foged N, Nielsen E, Elbirk A, Rohr N, Svendsen V, Birkeland SA. Fine-Needle aspiration cytology during treatment with orthoclone monoclonal antibody OKT3 for acute cellular rejection after renal transplantation. Transplant Proc 1988; 20: 626–628.
  • Häyry P, von Willebrandt E. Practical guidelines for fine needle aspiration biopsy of human renal allografts. Ann. Clin Res 1981; 13: 288–306.
  • Jørgensen KA, Rohr N, Elbirk A, Svendsen V, Birkeland SA. Minnesota-ALG, forced diuresis, careful control of hydration, virus infection prophylaxis and dopamine infusion in human renal transplantation. Transplant Proc 1992; 24: 358.
  • Jørgensen KA, Strate M, Svendsen V, Rohr N, Elbirk A, Birkeland SA. Fine-needle aspiration biopsy during and after OKT3. Transplant Proc 1989; 21: 3594.
  • Jørgensen KA, Strate M, Svendsen V, Rohr N, Elbirk A, Birkeland SA. Are FNAB correction factors correct? Transplant Proc 1989; 21: 3603.
  • Legendre C, Kreis H, Bach JF, Chatenoud L. Prediction of successful allograft rejection retreatment with OKT3. Transplantation 1992; 53: 87–90.
  • Ortho multicenter transplant study group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. New Engl J Med 1985; 313: 337–342.
  • Shield CF, Cosimi AB, Tolkoff-Rubin N, Rubin RH, Herrin J, Russel PS. Use of antithymocyte globulin for reversal of acute allograft rejection. Transplantation 1979; 28: 461–464.
  • Shroeder TJ, First MR, Mansour ME, et al. Antimurine antibody formation following OKT3 therapy. Transplantation 1990; 49: 48–51.
  • Simonian SJ, Lyons P, Chvala R, et al. Reversal of acute cadaveric renal allograft rejection with added ATG treatment. Transplant Proc 1983; 25: 604–607.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.